PER-055-16已完成未知
A STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 218
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Provision of signed informed consent prior to any study specific procedures
- •2. Female or male aged ≥18 years at the time of consent
- •3. eGFR ≥25 and ≤75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1
- •4. UACR ≥200 and ≤5000 mg/g at visit 1
- •5. Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated
排除标准
- •Exclusion criteria is shared in Section 3.2 of the protocol (pages 26-27) there are 17 exclusion criteria
研究者
相似试验
已完成
3 期
Dapa-CKDChronic Kidney DiseaseJPRN-jRCT2080223905AstraZeneca KK240
进行中（未招募）
1 期
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.Chronic kidney disease (CKD)MedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2016-003896-24-DKAstraZeneca AB4,000
进行中（未招募）
1 期
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.Chronic kidney disease (CKD)EUCTR2016-003896-24-HUAstraZeneca AB4,000
进行中（未招募）
1 期
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.Chronic kidney disease (CKD)EUCTR2016-003896-24-DEAstraZeneca AB4,000
进行中（未招募）
1 期
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.EUCTR2016-003896-24-SEAstraZeneca AB4,000